Prior sorafenib use >  days and/or grade  or  sorafenib related toxicity; note that prior chemotherapy for HCC or a different cancer is allowable
Participants may not have had prior use of PARP inhibitors; patients may not have received prior treatment affecting the VEGF pathway including but not limited to thalidomide, bevacizumab, sunitinib, or sorafenib
One prior line of therapy which must include sorafenib or participant must have progressed or been intolerant to sorafenib for participants not eligible for transarterial chemoembolization. Participants who had sorafenib for locally advanced disease or are intolerant to sorafenib are eligible. Participants may have had clinical progression only following sorafenib or local therapy.
Presence of at least one measurable lesion according to RECIST v.. c-i) FGF single agent-Phase I and Phase II, Group : Patients with HCC or advanced solid tumors, who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists. c-ii) FGF single agent-Phase II, Groups  and : HCC patients previously treated with sorafenib for advanced HCC with documented disease progression during or after discontinuation of sorafenib treatment, or intolerance to sorafenib treatment c-iii) FGF in combination with PDR:Advanced HCC patients who have received up to  previous lines of systemic treatment and one treatment must have included sorafenib with documented disease progression during or after discontinuation of sorafenib treatment, or intolerance to sorafenib treatment
Previous treatment with vemurafenib or any other BRAF inhibitor (prior sorafenib is allowed)
Previous BRAF inhibitor use such as vemurafenib, GSK or sorafenib
Patients who have received targeted prior VEGFR or FGFR-targeted agents (i.e. sunitinib, pazopanib, sorafenib, bevacizumab, axitinib, etc.)
COHORT B, GROUP : HEPATOCELLULAR CARCINOMA: Patients are not required to have failed sorafenib
For patients that have refused treatment with sorafenib, the benefits of sorafenib have been discussed in detail with the patient.
Immunotherapy-naive and have either progressed on, are intolerant to, or refused treatment with sorafenib. Subjects who receive treatment with systemic therapies other than sorafenib are not eligible.
Prior treatment with a BRAF inhibitor such as vemurafenib or dabrafenib (previous treatment with sorafenib is allowed)
Patients must be off sorafenib for at least four days prior to TACE treatment
Participants who have received prior sorafenib or anti-PD therapy for HCC
Inability to tolerate first-line treatment with sorafenib (e.g., unacceptable toxicity), tumor progression on sorafenib, patient preference to stop sorafenib and for alternative therapy/trial, or patient preference to forgo sorafenib for alternative therapy/trial
Patients who have received sorafenib or other systemic therapies for treatment of HCC in the past
Have documented objective radiographic progression after stopping treatment with sorafenib or else intolerance to sorafenib; intolerance to sorafenib is defined as: Common Terminology Criteria for Adverse Events (CTCAE) grade >=  drug-related adverse event(s) which both a) persisted in spite of comprehensive supportive therapy according to institutional standards and b) persisted or recurred after sorafenib treatment interruption of at least  days and dose reduction by one dose level; patients treated on sorafenib as the last treatment may start pembrolizumab at least  days after the last dose of sorafenib
Had prior systemic therapy for HCC other than sorafenib, or intercurrent local therapy to the liver tumor between sorafenib and study drug
Has received sorafenib within  days of first dose of study medication
Documented progression or intolerance to sorafenib as demonstrated by:\r\n* Radiographic (by modified [m]RECIST) or symptomatic progression on/after sorafenib\r\n* Intolerance to sorafenib consisting of Common Terminology Criteria for Adverse Events (CTCAE) grade  or greater during drug-related adverse event which persisted in spite of comprehensive supportive therapy according to institutional standards AND persisted or recurred after sorafenib treatment interruption of at least  days and dose reduction by one dose level (to  mg once daily)
Patients may receive concurrent capecitabine or sorafenib at the discretion of the treating physicians
Patients who have received previous anti-angiogenic treatment (experimental or marketed: bevacizumab, thalidomide, CP-, sunitinib, sorafenib or others)
Prior systemic therapy with a small molecule oral kinase inhibitor, including but not limited to: pazopanib, sunitinib, sorafenib, everolimus, sirolimus, vemurafenib, dasatinib and trametinib
If sorafenib was previously administered, intolerance to sorafenib
Patients who have received sorafenib or other systemic therapies for treatment of HCC in the past
Prior Y TARE or sorafenib is not allowed
Patients who have received targeted therapy (e.g., sunitinib, sorafenib, pazopanib), except ALK inhibitors, =<  weeks prior to starting study drug
Inability to tolerate first-line treatment with sorafenib (e.g., unacceptable toxicity), tumor progression on sorafenib, patient preference to stop sorafenib and for alternative therapy/trial, or patient preference to forgo sorafenib for alternative therapy/trial\r\n* Note:\r\n** Unacceptable toxicities due to sorafenib include, but are not limited to, the following drug-induced adverse events including: hepatitis, skin rash (grade  or higher), hypertension (grade  or higher), hand-foot skin reaction (grade  or higher), QT prolongation (grade  or higher), and/or diarrhea (grade  or higher)\r\n** Patient preference to stop sorafenib for alternative therapy/trial will include the following indications: the aforementioned adverse events at lesser grades for which the patient is unwilling to continue therapy, as well as situations in which the patient deems the side effects to be intolerable with their quality of life; examples include, but are not limited to, intolerable nausea, vomiting, abdominal pain, fatigue, loss of appetite, and weight loss\r\n** Patient preference to forgo sorafenib for alternative therapy/trial is based upon the patients' right for autonomy; this allows them to refuse or choose their treatment; the practitioner will always act in the best interest of the patient and recommend that the patient start with known life-prolonging therapies before enrolling in a clinical trial of an investigational agent that has not been determined to be safe and effective in patients with liver cancer
Sorafenib\r\n* Creatinine (Crt) < . X ULN
History of hypersensitivity to sorafenib for vemurafenib/sorafenib arm
Patients must have received prior systemic sorafenib treatment for HCC with documented progression during or after discontinuation of sorafenib treatment (for France only: patients must have received at least  weeks of prior sorafenib treatment), or are intolerant to sorafenib (defined as documented Grade  or  adverse events that led to sorafenib discontinuation),.
Patient is receiving sorafenib (Nexavar) as a monotherapy in their originating protocol. Patients who were being treated with sorafenib (Nexavar) in combination with other chemotherapies in the original study, but continued on single agent sorafenib (Nexavar) after discontinuation of the combination agent will be eligible.
Patients who are receiving concurrent combination with sorafenib (Nexavar) and capecitabine in their originating Study  (RESILIENCE) will be eligible.
Expansion cohort (HCC): histologically or cytologically confirmed diagnosis of hepatocellular carcinoma who are Child-Pugh class A and who were previously treated with sorafenib or refused sorafenib
Hepatocellular carcinoma cohort specific criteria:\r\n* Patients must have a histologically proven diagnosis of hepatocellular carcinoma that is not amenable to curative surgical therapeutic options\r\n* Patients must not be good candidates for locoregional therapy as determined by the investigator (ie diffuse multifocal disease, vascular involvement, etc)\r\n* Patients must have had evidence of radiologic progression on sorafenib or have had intolerance to sorafenib as defined by the recurrence of clinically significant toxicities despite a minimum of one dose reduction and appropriate supportive care; patients who refuse sorafenib are eligible with documentation of refusal by the treating physician\r\n* Patients may have received other treatment for HCC such as embolization, chemoembolization, intra-arterial chemotherapy, ethanol injection, ablative therapy, cryosurgery, or other locoregional or targeted therapy\r\n* Patients must have a Child Pugh score of  points or less \r\n* International normalized ratio (INR) =< . or prothrombin time =<  seconds above control\r\n* Patients with hepatitis B infection must be on appropriate anti-viral therapy
No prior systemic cytotoxic chemotherapy or targeted therapy (including sorafenib) for HCC
Pretransplant treatment with sorafenib tosylate (sorafenib) not >  months (not exceeding  months of treatment, total)
Prior use of any systemic chemotherapy for HCC, with the exception of sorafenib
Has documented objective radiographic progression during or after treatment with sorafenib or intolerance to sorafenib.
Has received sorafenib within  days of first dose of study drug.
Has had prior systemic therapy for HCC in the advanced (incurable) setting other than sorafenib, prior to the start of study drug.
Received prior sorafenib.
Have received more than one prior antiangiogenic agent (that is, bevacizumab, sorafenib, sunitinib) for TCC of the urothelium.
Must have received at least two prior lines of systemic therapy, including at least one VEGFR-targeting TKI (e.g., sunitinib, sorafenib, pazopanib, cabozantinib)
Subject must have received sorafenib treatment and either:
have had documented radiographic or symptomatic progression during or after sorafenib therapy; OR
be intolerant of sorafenib (defined as Grade  drug-related adverse event which ) persisted in spite of comprehensive supportive therapy according to institutional standards AND ) persisted or recurred after sorafenib treatment interruption of at least  days and dose reduction by one dose level (to  mg once daily) AND/OR Grade  drug-related adverse event which ) persisted in spite of comprehensive supportive therapy according to institutional standards OR ) persisted or recurred after sorafenib treatment interruption of at least  days and dose reduction by one dose level (to  mg once daily); OR must have documented refusal of sorafenib;
Prior treatment with sorafenib or tivozanib.
Prior systemic treatment for the treatment of HCC, including sorafenib
For Cohort : has documented objective radiographic progression after stopping treatment with sorafenib or else intolerance to sorafenib
For Cohort : has received sorafenib within  days of first dose of study drug
For Cohort : had prior systemic therapy for HCC other than sorafenib, or intercurrent local therapy to the liver tumor between sorafenib and study drug
Patients who have exhibited hypersensitivity reactions to regorafenib and/or a structural compound, biological agent, or formulation (e.g., sorafenib)
Has histopathologically or cytologically confirmed HCC, Child-Pugh Class A, with documented disease progression during or after discontinuation of sorafenib therapy, or intolerance of sorafenib therapy, and an ?-fetoprotein (AFP) ? .x upper limit of normal
Subject received prior systemic treatment for HCC with sorafenib or other anti-VEGF therapy and had confirmed disease progression or discontinued treatment due to a drug-related toxicity. Subject may have received  line of systemic therapy before or after sorafenib/anti-VEGF treatment.
For patients in the sorafenib tosylate (sorafenib) cohort, no prior therapy with sorafenib is allowed and at least  line of prior therapy is required including prior: VEGF-targeting therapy (such as sunitinib, axitinib, tivozanib, bevacizumab), mTOR-targeting therapy (such as everolimus, temsirolimus), immunotherapy (such as anti-PD- or anti-PD-L), cytokine therapy (such as interleukin-, interferon-alpha [IFN-a]) or cytotoxic systemic chemotherapy allowed
Patients who have had prior anti-angiogenic therapy, including but not limited to sorafenib, brivanib, bevacizumab, or sunitinib; prior treatment with liver directed, ablative or surgical therapies will be permitted as long as there is documented progression justifying the need for starting sorafenib therapy
Patients with prior or current treatment of sorafenib are excluded
Histologically proven advanced MPM, advanced peritoneal mesothelioma (for dose escalation cohort only) or non-squamous NSCLC (stage IIIB/IV) who have not been treated with prior chemotherapy or immunotherapy, except that NSCLC subjects with EGFR mutant or ALK positive must have had an EGFR tyrosine kinase inhibitor (TKI) or ALK inhibitor and progressed or been shown to be intolerant of therapy prior to enrolling in this trial, if such ALK inhibitor and EGFR targeted therapy are approved and available in the country in which patients are being enrolled OR Histologically proven metastatic uveal melanoma who have not been treated with prior chemotherapy (MTD cohort only), OR Histologically proven HCC who have failed (PD and/or side effects-been intolerant of) treatment with sorafenib. Failure is defined as having progressed radiographically on, or been intolerant to prior systemic therapy. Intolerance is defined as discontinuation due to an AE(s) on prior systemic therapy that was unacceptable to the treating physician and / or patient, with or without dose interruption and modification. Failure requires at least  days of treatment with sorafenib, except for a subject that has had a severe allergic reaction to sorafenib at any time, even less than  days of treatment with sorafenib and thus it would be imprudent to re-challenge them with that agent. Cirrhotic status of Child-Pugh grade A-B must be present. Child-Pugh status should be determined based on clinical findings and laboratory data during the screening period (Appendix E). Subjects on anti-coagulants are to receive  point for their INR status, as they are presumed to have a <. baseline PT/INR.\, OR Histologically proven high-grade glioma who have failed (PD and/or side effects) treatment with radiotherapy  temozolomide, OR Sarcomatoid cancer of any line.
Prior systemic therapy for the treatment of HCC, including sorafenib
Prior use of sorafenib
Prior treatment with sorafenib as single agent or in combination, with no less than  mg once every other day dose of sorafenib, with radiologic evidence of progression of disease
Patients who have had prior anti-angiogenic therapy, including but not limited to sorafenib, brivanib, bevacizumab, or sunitinib
The patient has received any investigational agents within  weeks prior to their first dose of sorafenib
Failure to prior treatment with sorafenib (defined as documented radiological progression according to the radiology charter). Randomization needs to be performed within  weeks after the last treatment with sorafenib.
Tolerability of prior treatment with sorafenib defined as not less than  days at a minimum daily dose of  mg QD within the last  days prior to withdrawal.
Sorafenib treatment within  weeks of randomization.
Prior systemic treatment for HCC, except sorafenib.
Permanent discontinuation of prior sorafenib therapy due to sorafenib related toxicity.
Intolerance of prior treatment with bevacizumab, pazopanib, sorafenib, or sunitinib; Note: subjects who required a dose reduction of pazopanib, sorafenib, or sunitinib during prior therapy MAY be eligible if they tolerated the agent after dose level reduction (to a minimum of dose level - as defined in this protocol)
Patients may have received any prior therapy deemed necessary for induction of remission except for patients whom have progressed while on sorafenib; patients who have responded to sorafenib previously are eligible for enrollment on the protocol
Prior use of pazopanib or other agents targeting angiogenesis pathway (such as bevacizumab, sunitinib, or sorafenib) in the metastatic setting
For Parts A & B: Have received sorafenib and have progressed or were intolerant to sorafenib or are ineligible for sorafenib treatment. For Part C: not received previous systemic treatment. For Part D: have received sorafenib and have progressed or were intolerant to sorafenib or are ineligible for sorafenib treatment or have not received prior systemic treatment.
For Parts A, B, and D: have discontinued sorafenib for at least  weeks
SORAFENIB ARM: platelets >= ,/mL
SORAFENIB ARM: history of hypersensitivity to sorafenib or any component of the formulation
Prior sorafenib is allowed as long as toxicity from ongoing is =< grade  and prior intolerance of  mg sorafenib PO daily is felt amenable, by the principal investigator, to supportive care measures or dose modifications
Previous treatment with anthracycline antibiotics (e.g. Doxorubicin) or sorafenib.
Agree to abstain from donating blood while taking CC- or sorafenib and following discontinuation of their use.
Documented progression on or after treatment with sorafenib, confirmed by the Investigator upon review of appropriate imaging documentation
Mandatory tumor biopsy at study entry (pre-randomization, unless already collected after sorafenib progression but within  months of enrollment and no systemic anticancer therapies received)
Prior systemic treatment for advanced liver cancer other than sorafenib-including therapy
Previous treatment with sorafenib for more than  weeks during the previous  months; prior sorafenib-related toxicity
For Part  and , the patient has unresectable disease and has been previously treated with sorafenib, has declined treatment with sorafenib, or does not have access to sorafenib.
Previously treated with sorafenib for greater than or equal to  weeks and discontinued sorafenib treatment at least  days prior to Day  due to either intolerance or radiographic progression
Prior systemic anticancer treatment for advanced HCC (except for sorafenib as described in the inclusion criteria)
Prior adjuvant therapy with sorafenib or another Raf/VEGF inhibitor
Prior treatment with sorafenib or other RAF/VEGF targeted therapies.
Patients who have received targeted therapy (e.g. sunitinib, sorafenib, pazopanib) =<  week prior to starting study drug, or who have not recovered from the side effects of such therapy
Patients who have received prior treatment with sorafenib are eligible, as long as the sorafenib was not given in combination with cyclosphosphamide and/or topotecan. Patients with tumor relapse/progression while on sorafinib or having dose modifications or experiencing toxicity that required sorafenib to be discontinued are also ineligible to participate in this study.
Patients must be candidates for sorafenib
Previous treatment with sorafenib
Patients with known hypersensitivity to sorafenib or any other component of sorafenib.
Prior use of sorafenib
Contraindications to sorafenib
Prior therapy against VEGF or VEGFRs including, but not limited to bevacizumab, sunitinib, sorafenib, pazopanib, motesanib (AMG), or cediranib (AZD), is permitted so long as the agent does not have any known activity against DLL and the last dose received s at least  weeks prior to first dose of MEDI.
Known or suspected allergy or hypersensitivity to any component of TH-, sorafenib, or any of the sorafenib excipients
Radioembolization within  weeks of day  dosing of sorafenib
PHASE I: Prior systemic therapy with sorafenib is allowed
PHASE II: Prior systemic therapy with sorafenib is allowed
Subjects must receive st dose of sorafenib - days prior to administration of SRS
Previously received mapatumumab or sorafenib.
Subject must have progressive disease after therapy consisting of one of the Food and Drug Administration (FDA)-approved agents for therapy of metastatic renal cell carcinoma, including but not limited to: sorafenib, sunitinib, or temsirolimus
Participants who have relapsed while on sorafenib therapy
Patients may not be receiving any other investigational agents.\r\n* Note: it is acceptable to be on combination therapy including either sorafenib, regorafenib, and/or sunitinib.
Patients receiving sorafenib at the time of enrollment and those who are scheduled to receive sorafenib as part of a treatment plan are ineligible
No prior line of systemic therapy (includes participants who are sorafenib-nave)
For patients who will receive enzalutamide monotherapy, failure or intolerance of prior sorafenib is required for enrollment; for patients who will receive combination therapy, prior sorafenib is excluded
Sorafenib was the only systemic therapy for HCC and was discontinued for disease progression or intolerance (Main Global and ME Cohorts only).
The participant received one prior systemic therapy regimen, excluding prior sorafenib, for the treatment of HCC (OLE Cohort only).
Subjects must be planned for treatment with approved treatment doses of a VEGF receptor TKI (e.g., sunitinib, pazopanib, cabozantinib, axitinib, sorafenib, lenvatinib)
